Citius Pharmaceuticals Inc (CTXR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.60 (+2.06%), Market cap $0.02B, 52-week low–high $0.59 ~ $2.21.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, Ne
Financial statements, price targets, institutional (13F) holdings and related news for Citius Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Citius Pharmaceuticals Inc trades at $0.60 (+2.06%). Real-time quotes and charts are available on BlackAll Trade.
Citius Pharmaceuticals Inc has a market cap of about $0.02B.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy